Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINASTRIN 24 FE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of acne (off-label),Treatment of dysmenorrhea (off-label)
Prevention of pregnancy
One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-27 hours. Clinical context: Steady-state achieved within 5-10 days; half-life supports once-daily dosing.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol undergoes first-pass metabolism in the liver via CYP3A4 and is extensively conjugated with glucuronic acid and sulfate. Norethindrone acetate is deacetylated to norethindrone, which is metabolized primarily via reduction and conjugation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Urine (primarily as glucuronide conjugates; ethinyl estradiol and norethindrone metabolites) and feces. Approximately 40% of norethindrone metabolites are excreted in urine and 60% in feces. Ethinyl estradiol is excreted as glucuronide and sulfate conjugates in urine (40%) and feces (60%).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin (not SHBG).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 4.0 L/kg; ethinyl estradiol: 15-20 L/kg (distributes extensively into tissues; no specific clinical significance beyond high distribution).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~64% (first-pass metabolism reduces bioavailability); ethinyl estradiol ~40% (variable due to presystemic conjugation).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No specific dose adjustment guidelines; use with caution in patients with renal impairment. Monitor for fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not approved for use before menarche. After menarche, same adult dosing applies for adolescents: one tablet orally daily.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use after menopause. In elderly women of reproductive age, same adult dosing applies; consider increased risk of thromboembolic events.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use. Women over 35 who smoke should not use this drug.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders, including venous thromboembolism, myocardial infarction, and stroke; highest in smokers >35 years. Use caution in patients with hypertension, diabetes, hyperlipidemia, migraine with aura, or history of cholestatic jaundice. Discontinue if jaundice, visual disturbances, or sudden severe headache occurs.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; age >35 and smoking.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; avoid concurrent use. No other significant food interactions. Iron tablets should be taken with food to reduce gastrointestinal upset.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: No increased risk of major birth defects based on epidemiological studies. Second and third trimesters: Use may cause fetal harm due to potential androgenization of female fetuses and other adverse effects from progestin exposure. Discontinue if pregnancy occurs.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of progestins and estrogens are excreted in breast milk. M/P ratio not established. Use with caution in nursing mothers; may reduce milk production and quality. Consider alternative contraception.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Not applicable; drug is contraindicated during pregnancy. No dose adjustment is possible as use is contraindicated.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
MINASTRIN 24 FE is a combination oral contraceptive containing norethindrone acetate and ethinyl estradiol, with ferrous fumarate as a dietary supplement. It has a 24/4 regimen, which may reduce hormone-free interval symptoms. The iron tablets (ferrous fumarate) are placebo and do not affect contraception; they are intended to help offset iron loss during menstruation. Patients with a history of venous thromboembolism, migraine with aura, or certain cancers should not use this drug. Counsel patients to take at the same time daily. Breakthrough bleeding is common in the first few cycles. Missed pill management: if one active pill is missed, take it as soon as remembered, even if taking two in one day. If two or more active pills are missed, use backup contraception for 7 days.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, preferably after the evening meal. The 24 light blue-green pills are active hormones; the 4 brown pills are iron supplements (placebo for contraception).,If you miss a pill, refer to the package insert or consult your healthcare provider. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, headache, and spotting. These often improve after 2–3 cycles.,Do not smoke while taking this medication; smoking increases the risk of serious cardiovascular events, especially in women over 35.,This medication does not protect against HIV or other sexually transmitted infections.,Tell your healthcare provider about all medications you take, especially antibiotics, anticonvulsants, and St. John's wort, as they may reduce effectiveness.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINASTRIN 24 FE vs ALYACEN 1/35, answered by our medical review team.
MINASTRIN 24 FE is a Oral Contraceptive that works by Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINASTRIN 24 FE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINASTRIN 24 FE is: One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINASTRIN 24 FE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINASTRIN 24 FE is classified as Category C. First trimester: No increased risk of major birth defects based on epidemiological studies. Second and third trimesters: Use may cause fetal harm due to potential androgenization o. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.